Home » Newsletters » BioWorld Science

BioWorld Science

May 26, 2014

View Archived Issues

Pfizer researchers design nicotine vaccines with higher avidity

Gilead's GS-5806 effective in phase IIa RSV trial

TxCell's Col-Treg receives Advanced Therapy Medicinal Product designation

Extended recombinant PTH treatment demonstrates good efficacy for hypoparathyroidism

Novel uPAR-derived peptide tested for ocular angiogenesis-related diseases

Isis Pharmaceuticals reports data for ISIS-FXI-Rx in prevention of venous thrombosis

Dabigatran etexilate antidote progresses into next stage of clinical investigation

Novel non-retinoid therapeutic for AMD significantly reduces RBP4 plasma levels

H3 Biomedicine and Selvita achieve milestone in oncology collaboration

Bifunctional shRNA shows efficacy for the treatment of Ewing's sarcoma

Novel patent describes Wnt signaling inhibitors

Imatinib receives FDA orphan drug designation for PML

Nerviano Medical Sciences reports discovery of new PARP-1 inhibitors

Volitinib enters phase II trial in renal cell carcinoma

Toray Industries discloses nAChR alpha-7 agonists

Emory University synthesizes novel 7,8-dihydroxyflavone prodrugs

NeurOp selects development candidate for subarachnoid hemorrhage

Forxiga launched in Japan for the treatment of type 2 diabetes

Taisho Pharmaceutical launches Lusefi in Japan

Astellas launches Xtandi in Japan for prostate cancer

FDA approves dalbavancin for bacterial skin and skin structure infections

Vectibix plus FOLFOX approved in U.S. for wild-type KRAS metastatic colorectal cancer

GSK submits regulatory submission for umeclidinium monotherapy in Japan

Lonsurf combination tablet scheduled for launch in Japan

CHMP issues positive opinion for Translarna for nonsense mutation DMD

Dainippon proposes changes to prepare for global development of business

EMA committee recommends approval of obinutuzumab

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...